1. Medtech Insight
  2. >>Policy & Regulation

Boston Scientific Pays $189M To Resolve Pelvic Mesh Cases

 
• By Elizabeth Orr

The settlement puts to rest product liability and patient safety suits in 47 states and the District of Columbia.

surgical-knife-tape
• Source: Shutterstock

Boston Scientific Corporation is paying to resolve remaining pelvic mesh lawsuits in 47 states plus the District of Columbia, bringing long-running product safety litigation closer to a final resolution.

The $188.7m settlement was announced on 23 March and did not involve any admission of guilt or responsibility on the part of Boston Scientific. The lawsuit alleged that the company...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Policy & Regulation

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

FDLI: Clinical Labs Face Uncertainty After Texas Court’s LDT Ruling

 
• By Elizabeth Orr

A Texas court's decision against US FDA regulation of lab-developed tests (LDTs) has introduced new uncertainties for clinical labs. Industry stakeholders are now worried about potential future regulations while also managing existing compliance requirements. Recent conference discussions underscored the complexities of FDA oversight.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.